Xarelto Fails Phase III Trial in ESUS

Bayer and Johnson & Johnson’s Janssen Research & Development have acknowledged that their Xarelto ® (rivaroxaban) has failed a Phase III trial assessing the blockbuster anticoagulant in patients with a recent embolic stroke of undetermined source (ESUS).The companies said the Phase III NAVIGATE ESUS missed its primary efficacy endpoint of superiority over aspirin in reducing the risk of stroke (ischemic, hemorrhagic, and undefined stroke; transient ischemic attack with positive